 John Kim
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 15 | 2025 | 664 | 3.720 |
Why?
| | Idiopathic Pulmonary Fibrosis | 20 | 2025 | 692 | 3.270 |
Why?
| | Cardiac Surgical Procedures | 4 | 2022 | 611 | 1.350 |
Why?
| | Cardiopulmonary Bypass | 2 | 2022 | 219 | 1.160 |
Why?
| | Heart Defects, Congenital | 4 | 2021 | 910 | 1.110 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2023 | 303 | 1.070 |
Why?
| | Thrombosis | 2 | 2021 | 400 | 0.930 |
Why?
| | Hemodynamics | 2 | 2021 | 1118 | 0.890 |
Why?
| | HLA-DRB1 Chains | 1 | 2025 | 110 | 0.820 |
Why?
| | Poisoning | 1 | 2025 | 119 | 0.800 |
Why?
| | Lung | 12 | 2025 | 4116 | 0.790 |
Why?
| | Shock | 1 | 2025 | 110 | 0.790 |
Why?
| | Pulmonary Fibrosis | 2 | 2024 | 395 | 0.760 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 98 | 0.760 |
Why?
| | Mucin-5B | 2 | 2025 | 234 | 0.760 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 39 | 0.740 |
Why?
| | Pyridones | 2 | 2023 | 209 | 0.740 |
Why?
| | Tomography, X-Ray Computed | 14 | 2025 | 2770 | 0.740 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2025 | 390 | 0.740 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2023 | 143 | 0.720 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 231 | 0.680 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 92 | 0.670 |
Why?
| | Biomarkers | 9 | 2025 | 4302 | 0.670 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2021 | 64 | 0.640 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 469 | 0.620 |
Why?
| | Indoles | 2 | 2023 | 507 | 0.620 |
Why?
| | Resistin | 1 | 2019 | 12 | 0.610 |
Why?
| | Rheumatology | 4 | 2024 | 133 | 0.610 |
Why?
| | Arthritis, Rheumatoid | 3 | 2025 | 1180 | 0.600 |
Why?
| | Proteomics | 6 | 2025 | 1188 | 0.580 |
Why?
| | Asymptomatic Diseases | 1 | 2019 | 104 | 0.580 |
Why?
| | Sleep Deprivation | 1 | 2021 | 206 | 0.580 |
Why?
| | Ketorolac | 1 | 2018 | 33 | 0.550 |
Why?
| | Lung Injury | 1 | 2021 | 249 | 0.550 |
Why?
| | Platelet Aggregation | 1 | 2018 | 99 | 0.540 |
Why?
| | Humans | 63 | 2025 | 145783 | 0.540 |
Why?
| | Leptin | 1 | 2019 | 248 | 0.540 |
Why?
| | Vital Capacity | 4 | 2023 | 292 | 0.530 |
Why?
| | Adiponectin | 1 | 2019 | 242 | 0.530 |
Why?
| | Electrocardiography | 1 | 2021 | 668 | 0.520 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 198 | 0.520 |
Why?
| | Aged | 24 | 2025 | 26217 | 0.510 |
Why?
| | Male | 35 | 2025 | 73011 | 0.450 |
Why?
| | Prospective Studies | 14 | 2025 | 8078 | 0.450 |
Why?
| | Psychotherapy, Brief | 1 | 2015 | 41 | 0.430 |
Why?
| | Female | 36 | 2025 | 79045 | 0.420 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 166 | 0.420 |
Why?
| | Sleep | 1 | 2021 | 889 | 0.410 |
Why?
| | Social Work | 1 | 2015 | 85 | 0.410 |
Why?
| | Tissue Expansion Devices | 1 | 2013 | 5 | 0.390 |
Why?
| | Middle Aged | 23 | 2025 | 36309 | 0.380 |
Why?
| | Breast Implants | 1 | 2013 | 32 | 0.380 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 264 | 0.360 |
Why?
| | Free Tissue Flaps | 1 | 2013 | 54 | 0.360 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 25 | 0.320 |
Why?
| | Mammaplasty | 1 | 2013 | 142 | 0.320 |
Why?
| | Genome-Wide Association Study | 4 | 2025 | 1430 | 0.310 |
Why?
| | Child | 14 | 2025 | 22740 | 0.310 |
Why?
| | Thrombelastography | 3 | 2020 | 192 | 0.310 |
Why?
| | Disease Progression | 5 | 2025 | 2865 | 0.300 |
Why?
| | Critical Care | 1 | 2016 | 702 | 0.300 |
Why?
| | Independent Living | 2 | 2021 | 116 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 328 | 0.290 |
Why?
| | Postoperative Period | 2 | 2021 | 351 | 0.280 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.280 |
Why?
| | Muscle, Skeletal | 6 | 2011 | 1791 | 0.280 |
Why?
| | Blood Coagulation Disorders | 2 | 2020 | 198 | 0.270 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1957 | 0.260 |
Why?
| | Adolescent | 6 | 2025 | 22577 | 0.240 |
Why?
| | Oxidants | 1 | 2006 | 99 | 0.230 |
Why?
| | Obesity | 1 | 2019 | 3118 | 0.230 |
Why?
| | Smoking | 2 | 2025 | 1477 | 0.220 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 568 | 0.220 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 62 | 0.220 |
Why?
| | Child, Preschool | 5 | 2025 | 11868 | 0.220 |
Why?
| | Cohort Studies | 7 | 2025 | 6033 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 4 | 2025 | 2399 | 0.200 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 178 | 0.200 |
Why?
| | Adult | 6 | 2024 | 40881 | 0.200 |
Why?
| | Eicosapentaenoic Acid | 1 | 2023 | 37 | 0.200 |
Why?
| | Smokers | 2 | 2025 | 138 | 0.200 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2025 | 127 | 0.190 |
Why?
| | Carbon Monoxide | 1 | 2023 | 82 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2024 | 532 | 0.190 |
Why?
| | Demography | 1 | 2024 | 282 | 0.190 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2933 | 0.190 |
Why?
| | Peptides, Cyclic | 1 | 2025 | 273 | 0.190 |
Why?
| | Antibody Formation | 1 | 2024 | 288 | 0.180 |
Why?
| | Methylprednisolone | 1 | 2022 | 59 | 0.180 |
Why?
| | Angiopoietin-2 | 1 | 2022 | 15 | 0.180 |
Why?
| | Acetylcysteine | 1 | 2022 | 139 | 0.180 |
Why?
| | Heart Failure | 2 | 2021 | 2326 | 0.180 |
Why?
| | Infant | 5 | 2025 | 10091 | 0.170 |
Why?
| | Insulin | 5 | 2022 | 2516 | 0.170 |
Why?
| | Alleles | 1 | 2025 | 896 | 0.170 |
Why?
| | Vasodilation | 1 | 2025 | 521 | 0.170 |
Why?
| | Myofibroblasts | 1 | 2023 | 149 | 0.170 |
Why?
| | Tomography | 1 | 2021 | 45 | 0.170 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2022 | 90 | 0.170 |
Why?
| | Respiratory System Abnormalities | 1 | 2021 | 18 | 0.170 |
Why?
| | Blood Loss, Surgical | 1 | 2022 | 114 | 0.160 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 297 | 0.160 |
Why?
| | Actigraphy | 1 | 2021 | 148 | 0.160 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1330 | 0.160 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5925 | 0.160 |
Why?
| | Femoral Vein | 1 | 2020 | 38 | 0.160 |
Why?
| | Lung Transplantation | 1 | 2024 | 332 | 0.160 |
Why?
| | Photoplethysmography | 1 | 2020 | 19 | 0.160 |
Why?
| | Treatment Outcome | 4 | 2024 | 11794 | 0.160 |
Why?
| | Heart Diseases | 1 | 2023 | 341 | 0.160 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 94 | 0.160 |
Why?
| | Arterial Switch Operation | 1 | 2020 | 16 | 0.160 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2393 | 0.160 |
Why?
| | Proof of Concept Study | 1 | 2020 | 89 | 0.150 |
Why?
| | Vital Signs | 1 | 2020 | 46 | 0.150 |
Why?
| | Promoter Regions, Genetic | 1 | 2025 | 1247 | 0.150 |
Why?
| | Risk Factors | 5 | 2025 | 10919 | 0.150 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 63 | 0.150 |
Why?
| | Body Mass Index | 2 | 2019 | 2447 | 0.150 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.150 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 251 | 0.150 |
Why?
| | Herniorrhaphy | 1 | 2020 | 76 | 0.150 |
Why?
| | Antibodies, Viral | 1 | 2024 | 674 | 0.150 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.150 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 76 | 0.150 |
Why?
| | Logistic Models | 1 | 2025 | 2139 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 57 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2021 | 328 | 0.140 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 123 | 0.140 |
Why?
| | Peritoneal Dialysis | 1 | 2020 | 100 | 0.140 |
Why?
| | Transcriptome | 2 | 2024 | 1042 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 587 | 0.140 |
Why?
| | Pulmonary Valve | 1 | 2020 | 102 | 0.140 |
Why?
| | Education, Nursing, Continuing | 1 | 2018 | 47 | 0.140 |
Why?
| | Oxidative Stress | 3 | 2011 | 1360 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1036 | 0.130 |
Why?
| | Learning Curve | 1 | 2018 | 71 | 0.130 |
Why?
| | Length of Stay | 2 | 2021 | 1350 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 481 | 0.130 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2017 | 30 | 0.130 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2020 | 288 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2024 | 869 | 0.130 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2020 | 221 | 0.130 |
Why?
| | Glucose | 6 | 2011 | 1049 | 0.130 |
Why?
| | Hand | 1 | 2018 | 157 | 0.130 |
Why?
| | Catheterization, Peripheral | 1 | 2018 | 120 | 0.130 |
Why?
| | Autoantibodies | 1 | 2025 | 1509 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 166 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 14254 | 0.120 |
Why?
| | Circadian Rhythm | 1 | 2021 | 513 | 0.120 |
Why?
| | Stroke Volume | 1 | 2020 | 655 | 0.120 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 55 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2181 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 730 | 0.120 |
Why?
| | Polysomnography | 1 | 2017 | 239 | 0.120 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 559 | 0.120 |
Why?
| | Adiposity | 1 | 2021 | 532 | 0.120 |
Why?
| | Scimitar Syndrome | 1 | 2016 | 10 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 136 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1925 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2023 | 6465 | 0.120 |
Why?
| | Rats, Zucker | 4 | 2011 | 32 | 0.120 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2016 | 61 | 0.120 |
Why?
| | Coronary Care Units | 1 | 2016 | 27 | 0.120 |
Why?
| | Nitrous Oxide | 1 | 2016 | 34 | 0.120 |
Why?
| | Hemoptysis | 1 | 2016 | 35 | 0.120 |
Why?
| | Algorithms | 2 | 2022 | 1851 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2123 | 0.110 |
Why?
| | Insulin Resistance | 3 | 2011 | 1244 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 346 | 0.110 |
Why?
| | Linear Models | 1 | 2017 | 849 | 0.110 |
Why?
| | Vaccination | 1 | 2024 | 1428 | 0.110 |
Why?
| | Pilot Projects | 1 | 2021 | 1898 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Calcium Channel Blockers | 1 | 2016 | 166 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Glycogen Synthase | 4 | 2007 | 6 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 874 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 835 | 0.100 |
Why?
| | China | 1 | 2015 | 274 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2020 | 769 | 0.100 |
Why?
| | Femoral Neoplasms | 1 | 2014 | 10 | 0.100 |
Why?
| | Muscle Neoplasms | 1 | 2014 | 9 | 0.100 |
Why?
| | Hydrogen Peroxide | 4 | 2011 | 335 | 0.100 |
Why?
| | Vasodilator Agents | 1 | 2016 | 330 | 0.100 |
Why?
| | Fever of Unknown Origin | 1 | 2014 | 13 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 718 | 0.100 |
Why?
| | Hemangioma | 1 | 2014 | 46 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1973 | 0.100 |
Why?
| | Scleroderma, Systemic | 2 | 2024 | 123 | 0.100 |
Why?
| | Arthralgia | 1 | 2014 | 61 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2020 | 962 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1711 | 0.090 |
Why?
| | United States | 4 | 2025 | 16126 | 0.080 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 95 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1247 | 0.080 |
Why?
| | Rats | 6 | 2011 | 5585 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 429 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 900 | 0.080 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2007 | 83 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2020 | 2977 | 0.060 |
Why?
| | Anticoagulants | 2 | 2023 | 748 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1276 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8347 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2023 | 17330 | 0.060 |
Why?
| | Free Radicals | 1 | 2006 | 105 | 0.060 |
Why?
| | Critical Illness | 2 | 2023 | 900 | 0.060 |
Why?
| | Renin | 1 | 2005 | 33 | 0.060 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 38 | 0.060 |
Why?
| | Tetrazoles | 1 | 2005 | 50 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1361 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2005 | 67 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2968 | 0.060 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.050 |
Why?
| | Spirometry | 1 | 2025 | 233 | 0.050 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 37 | 0.050 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 450 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 82 | 0.050 |
Why?
| | Myositis | 1 | 2024 | 57 | 0.050 |
Why?
| | Mouth | 1 | 2024 | 86 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 37 | 0.050 |
Why?
| | Vitamin K | 1 | 2023 | 46 | 0.050 |
Why?
| | California | 1 | 2025 | 473 | 0.050 |
Why?
| | Connective Tissue Diseases | 1 | 2024 | 85 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 209 | 0.050 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Blood Proteins | 1 | 2024 | 239 | 0.050 |
Why?
| | Pulmonary Emphysema | 1 | 2025 | 277 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2023 | 129 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 544 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2022 | 31 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 35 | 0.050 |
Why?
| | Quality Improvement | 1 | 2021 | 1296 | 0.040 |
Why?
| | Europe | 1 | 2023 | 421 | 0.040 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 178 | 0.040 |
Why?
| | Exome | 1 | 2023 | 229 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 508 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2022 | 54 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 232 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 457 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1378 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 413 | 0.040 |
Why?
| | Biological Transport | 3 | 2007 | 424 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 740 | 0.040 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 37 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1512 | 0.040 |
Why?
| | Genetic Variation | 1 | 2025 | 977 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 798 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 822 | 0.030 |
Why?
| | Creatinine | 1 | 2020 | 515 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1478 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 1038 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2022 | 2064 | 0.030 |
Why?
| | Genotype | 1 | 2022 | 1857 | 0.030 |
Why?
| | Trauma Centers | 1 | 2020 | 466 | 0.030 |
Why?
| | Lung Diseases | 1 | 2024 | 782 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 198 | 0.030 |
Why?
| | Fibroblasts | 1 | 2023 | 1028 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.030 |
Why?
| | Nurse's Role | 1 | 2018 | 149 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 788 | 0.030 |
Why?
| | Receptor, Insulin | 2 | 2007 | 93 | 0.030 |
Why?
| | Animals | 6 | 2011 | 38102 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1752 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2934 | 0.030 |
Why?
| | Signal Transduction | 2 | 2006 | 5224 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4330 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 1115 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 924 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2410 | 0.020 |
Why?
| | Phosphoproteins | 2 | 2005 | 337 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3170 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3211 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 762 | 0.020 |
Why?
| | Glycogen | 1 | 2007 | 55 | 0.020 |
Why?
| | Pyridines | 1 | 2011 | 609 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2014 | 853 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 2005 | 39 | 0.010 |
Why?
| | Angiotensin II | 1 | 2005 | 102 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 2005 | 62 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 981 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 332 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 247 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1708 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1049 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2005 | 383 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 440 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2525 | 0.010 |
Why?
| | Mice | 1 | 2005 | 18356 | 0.000 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|